Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer

Sorafenib and metronomic oral vinorelbine is active in advanced NSCLC. Baseline levels and changes in DCE parameters and CEC may be useful predictive biomarkers.